TMLZ-G46

TMLZ-G46: sourced facts only. name: "Subsequent optimization identified TMLZ-G46, which showed high affinity for ZNF207 (KD = 68 nM), potent antiproliferative activity against ZNF207-high glioma cells (IC50 = 0.93-2.07 μM), and strong inhibition of stemness (IC50 = 0.34-0.58 μM)." [PMID:41854173]; target: "Subsequent optimization identified TMLZ-G46, which showed high affinity for ZNF207 (KD = 68 nM), potent antiproliferative activity against ZNF207-high glioma cells (IC50 = 0.93-2.07 μM), and strong inhibition of stemness (IC50 = 0.34-0.58 μM)." [PMID:41854173]; developer: "School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China." [PMID:41854173]; stage: "In vivo, TMLZ-G46 achieved 83.7% tumor growth inhibition in subcutaneous glioblastoma (GBM) (grade IV) cell line-derived xenografts without detectable toxicity and significantly prolonged survival in an orthotopic GBM xenograft model, with efficacy comparable to temozolomide." [PMID:41854173]